Am­gen's Ote­zla notch­es an­oth­er PhI­II win; Califf earns ad­vo­ca­cy group­s' stamp of ap­proval

Am­gen’s block­buster Ote­zla just racked up an­oth­er Phase III win as it looks to con­tin­ue ex­pand­ing on its multi­bil­lion-dol­lar rev­enue stream.

The drug hit the pri­ma­ry end­point in a tri­al re­search­ing its use in mod­er­ate to se­vere gen­i­tal pso­ri­a­sis, Am­gen an­nounced in the topline read­out Wednes­day af­ter­noon. On top of that, all sec­ondary end­points were hit, demon­strat­ing “mean­ing­ful and sig­nif­i­cant im­prove­ments,” the com­pa­ny said.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.